Cargando…

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with risk factors such as age and smoking. Low-dose computed tomography screening can reduce lung cancer mortality. However, its effectiveness in Asian populations remains unclear. Most Asian women with lung cancer are n...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Feng, Shi, Rui, Hu, Lili, Chen, Ran, Wang, Daoyue, Lv, Xiazhi, Zhao, Yong, Huang, Wei, Yang, Yang, Zhou, Hongyang, Hong, Kaige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795014/
https://www.ncbi.nlm.nih.gov/pubmed/36591449
http://dx.doi.org/10.3389/fonc.2022.1059999
Descripción
Sumario:BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with risk factors such as age and smoking. Low-dose computed tomography screening can reduce lung cancer mortality. However, its effectiveness in Asian populations remains unclear. Most Asian women with lung cancer are non-smokers who have not been screened. We conducted a randomized controlled trial to evaluate the performance of low-dose computed tomography screening in a Chinese population, including high-risk smokers and non-smokers exposed to passive smoking. The baseline data are reported in this study. METHODS: Between May and December 2019, eligible participants were randomized in a ratio of 1:1:1 to a screening (two arms) or control cohort. Non-calcified nodules/masses with a diameter >4 mm on low-dose computed tomography were considered positive findings. RESULTS: In total, 600 patients (mean age, 59.1 ± 6.9 years) underwent low-dose computed tomography. Women accounted for 31.5% (189/600) of patients; 89.9% (170/189) were non-smokers/passive smokers. At baseline, the incidence of lung cancer was 1.8% (11/600). The incidence of lung cancer was significantly lower in smokers than in female non-smokers/passive smokers (1.0% [4/415] vs. 4.1% [7/170], respectively; P=0.017). Stage 0–I lung cancer accounted for 90.9% (10/11) of cases. CONCLUSIONS: We demonstrate the importance of including active smokers and female non-smokers/passive smokers in lung cancer screening programs. Further studies are needed to explore the risk factors, and long-term cost–benefit of screening Asian non-smoking women. CLINICAL TRIAL REGISTRATION: http://chictr.org.cn/showproj.aspx?proj=39003, identifier ChiCTR1900023197.